PBS path for Zolgensma ‘inactive’

By Megan Brodie 2 years ago | In Products
  • 2 years ago
First gene therapy considered by PBAC has faltered in post-PBAC processing.

6 December 2021 Novartis says it “remains committed to finding a pathway” for its┬áSpinal Muscular…

This is subscriber-only content. Please login to continue reading.